Phase 2RecruitingPriority 2 · High priorityNCT06854653
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Plain-language summary
This trial is testing PTX-100 for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 6 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
PTX-100 (DRUG): Peptidomimetic inhibitor of GGTase 1
PTX-100
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details